For example, many of the BTK inhibitors currently in clinical trials are reporting dose-limiting toxicities of thrombocytopenia and neutropina [28] in addition to dermatological toxicities [29], all of which are limiting their clinical uses. Here, BTK is linked to Thrombocytopenia.